Next earnings date: 12 Aug 2025
Sonnet BioTherapeutics Holdings, Inc. – NASDAQ:SONN
Sonnet BioTherapeutics Holdings stock price today
Sonnet BioTherapeutics Holdings stock price monthly change
Sonnet BioTherapeutics Holdings stock price quarterly change
Sonnet BioTherapeutics Holdings stock price yearly change
Sonnet BioTherapeutics Holdings key metrics
Market Cap | 4.72M |
Enterprise value | 1.05M |
P/E | -0.06 |
EV/Sales | 4.10 |
EV/EBITDA | -0.03 |
Price/Sales | 9.78 |
Price/Book | -0.71 |
PEG ratio | N/A |
EPS | -12.53 |
Revenue | N/A |
EBITDA | -16.86M |
Income | -12.92M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -11291.03% |
Oper. margin | -11292.51% |
Gross margin | 0% |
EBIT margin | -11292.51% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSonnet BioTherapeutics Holdings stock price history
Sonnet BioTherapeutics Holdings stock forecast
Sonnet BioTherapeutics Holdings financial statements
| Mar 2023 | 36.44K | -5.67M | -15562.29% |
|---|---|---|---|
| Jun 2023 | 36.85K | -3.94M | -10710.29% |
| Sep 2023 | 37.25K | -3.67M | -9869.12% |
| Mar 2024 | 0 | 365.42K |
| 2027 | 12.24K | -12.56M | -102597.89% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2024-08-14 | -0.76 | -5.6 |
|---|
| Mar 2023 | 13311326 | 7.94M | 59.67% |
|---|---|---|---|
| Jun 2023 | 10034810 | 6.61M | 65.93% |
| Sep 2023 | 5429478 | 5.65M | 104.16% |
| Mar 2024 | 5909409 | 2.85M | 48.31% |
| Mar 2023 | -4.69M | -261.25K | 14.64M |
|---|---|---|---|
| Jun 2023 | -6.17M | -12K | 1.81M |
| Sep 2023 | -4.55M | -170K | -17.69K |
| Mar 2024 | 723.79K | 0 | 41K |
Sonnet BioTherapeutics Holdings alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 12 |
| Apr 2024 | 12 |
| May 2024 | 12 |
| Jun 2024 | 12 |
| Jul 2024 | 12 |
Sonnet BioTherapeutics Holdings other data
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 60000 | 0 |
| May 2023 | 419855 | 0 |
| Jun 2023 | 10000 | 0 |
| Oct 2023 | 150000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | RAO RAGHU director | Warrant to Purchase Common Stock | 31,250 | $1.6 | $50,000 | ||
Purchase | RAO RAGHU director | Common Stock | 15,625 | $1.6 | $25,000 | ||
Purchase | MOHAN PANKAJ director, officer.. | Warrant to Purchase Common Stock | 68,750 | $1.6 | $110,000 | ||
Purchase | MOHAN PANKAJ director, officer.. | Common Stock | 34,375 | $1.6 | $55,000 | ||
Purchase | DEXTER SUSAN officer: Chief Technical Officer | Common Stock | 10,000 | $0.7 | $7,000 | ||
Purchase | DYRNESS ALBERT D. director | Common Stock | 23,255 | $0.47 | $10,883 | ||
Purchase | BHATT NAILESH director | Common Stock | 25,000 | $0.23 | $5,800 | ||
Purchase | MOHAN PANKAJ director, officer.. | Common Stock | 371,600 | $0.22 | $82,867 | ||
Purchase | MOHAN PANKAJ director, officer.. | Common Stock | 60,000 | $0.59 | $35,100 | ||
Purchase | KENNEY RICHARD T officer: Chief Medical Officer | Common Stock | 15,000 | $1.54 | $23,100 |
| Insider | Compensation |
|---|---|
| Dr. Pankaj Mohan Ph.D. (1965) Founder, Chairman. Chief Executive Officer & Pres | $792,170 |
Mr. Jay Cross (1970) Chief Financial Officer | $532,640 |
| Dr. John K. Cini Ph.D. (1953) Chief Scientific Officer & Co-Founder | $525,100 |
-
What's the price of Sonnet BioTherapeutics Holdings stock today?
One share of Sonnet BioTherapeutics Holdings stock can currently be purchased for approximately $3.1.
-
When is Sonnet BioTherapeutics Holdings's next earnings date?
Sonnet BioTherapeutics Holdings, Inc. is estimated to report earnings on Tuesday, 12 Aug 2025.
-
Does Sonnet BioTherapeutics Holdings pay dividends?
No, Sonnet BioTherapeutics Holdings does not pay dividends.
-
How much money does Sonnet BioTherapeutics Holdings make?
Sonnet BioTherapeutics Holdings has a market capitalization of 4.72M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 87.4% to 18.63K US dollars. Sonnet BioTherapeutics Holdings made a loss 7.44M US dollars in net income (profit) last year or -$5.6 on an earnings per share basis.
-
What is Sonnet BioTherapeutics Holdings's stock symbol?
Sonnet BioTherapeutics Holdings, Inc. is traded on the NASDAQ under the ticker symbol "SONN".
-
What is Sonnet BioTherapeutics Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sonnet BioTherapeutics Holdings?
Shares of Sonnet BioTherapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sonnet BioTherapeutics Holdings's key executives?
Sonnet BioTherapeutics Holdings's management team includes the following people:
- Dr. Pankaj Mohan Ph.D. Founder, Chairman. Chief Executive Officer & Pres(age: 60, pay: $792,170)
- Mr. Jay Cross Chief Financial Officer(age: 55, pay: $532,640)
- Dr. John K. Cini Ph.D. Chief Scientific Officer & Co-Founder(age: 72, pay: $525,100)
-
Is Sonnet BioTherapeutics Holdings founder-led company?
Yes, Sonnet BioTherapeutics Holdings is a company led by its founders Dr. Pankaj Mohan Ph.D. and Dr. John K. Cini Ph.D..
-
How many employees does Sonnet BioTherapeutics Holdings have?
As Jul 2024, Sonnet BioTherapeutics Holdings employs 12 workers.
-
When Sonnet BioTherapeutics Holdings went public?
Sonnet BioTherapeutics Holdings, Inc. is publicly traded company for more then 18 years since IPO on 31 Oct 2006.
-
What is Sonnet BioTherapeutics Holdings's official website?
The official website for Sonnet BioTherapeutics Holdings is sonnetbio.com.
-
Where are Sonnet BioTherapeutics Holdings's headquarters?
Sonnet BioTherapeutics Holdings is headquartered at 100 Overlook Center, Princeton, NJ.
-
How can i contact Sonnet BioTherapeutics Holdings?
Sonnet BioTherapeutics Holdings's mailing address is 100 Overlook Center, Princeton, NJ and company can be reached via phone at +60 9 375 2227.
Sonnet BioTherapeutics Holdings company profile:
Sonnet BioTherapeutics Holdings, Inc.
sonnetbio.comNASDAQ
12
Biotechnology
Healthcare
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Princeton, NJ 08540
CIK: 0001106838
ISIN: US83548R3030
CUSIP: 83548R105
